MADISON, WI--(Marketwire - October 15, 2009) - TomoTherapy Incorporated (NASDAQ: TOMO) announced today that the Institute Curie
Hospital in France has purchased a second TomoTherapy® radiation
therapy system, to support the increasing demand for intensity-modulated
radiation therapy (IMRT). The Institute Curie Hospital has been treating
cancer patients with TomoTherapy technology since March 2007, when it
became the first hospital in France to adopt the technology. Now, with this
most recent purchase, there are eight TomoTherapy systems in use in France
to treat patients with routine, complex and rare cancers.
"We typically treat our most complex cases -- such as sarcomas, head and
neck tumors with multiple treatment volumes, and lung, pancreatic and liver
cancers -- with TomoTherapy," said Dr. Alain Fourquet, head of the
Department of Radiation Oncology at the Institute Curie Hospital. "The
addition of a second unit will allow us to increase our ability to care for
more patients in need of advanced radiation therapy and enable us to expand
the types of indications we can treat to include pelvic tumors and some
complicated cases of breast cancer. In addition, we hope to use the second
TomoTherapy system to assist us in conducting prospective clinical trials
and research in physics projects."
The Institute Curie is a private foundation combining France's largest
cancer research center and a leading edge hospital. It was founded in 1909
by Marie Curie with the primary purpose of defeating cancer, and it
received state approval as a foundation in 1921. Internationally renowned
for its work in the diagnosis and treatment of cancers, the Institute Curie
serves as a reference center throughout the world on the implementation of
The second TomoTherapy system at Institute Curie Hospital will replace an
aging cobalt radiation machine. The small footprint of the TomoTherapy unit
will enable the hospital to install the new technology while minimizing the
need for extensive remodeling. The hospital decided to purchase its first
TomoTherapy system after the National Cancer Institute called for research
proposals to promote IMRT technology not previously available in France.
"The Institute Curie is among the most prestigious cancer research
facilities in the world and is well known for its high standard of care,"
said Patrice Lompech, TomoTherapy sales manager in France. "The hospital's
decision to expand its TomoTherapy practice is further validation of the
platform's power for treating a wide variety of cases and demonstrates the
confidence staff has in our platform, as they provide the highest quality
3D image-guided treatments for patients."
The Institute Curie will present three TomoTherapy treatment-related
abstracts at the Annual Meeting of the American Society for
Radiation Oncology (ASTRO) being held November 1-5, 2009, in Chicago.
The scientific papers highlight Institute Curie's research work involving
uncommon and clinically challenging cases in plasmocytoma and extensive
malignant lymphoma in conjunction with stem cell transplant, as well as
preliminary studies on the use of TomoTherapy technology in breast cancer
About TomoTherapy Incorporated
TomoTherapy Incorporated has developed, markets and sells the
TomoTherapy® Hi·Art® treatment system, an advanced radiation therapy
system for the treatment of a wide variety of cancers. The Hi·Art treatment
system combines integrated CT imaging with conformal radiation therapy to
deliver sophisticated radiation treatments with speed and precision while
reducing radiation exposure to surrounding healthy tissue. The company's
stock is traded on the NASDAQ Global Select Market under the symbol TOMO.
To learn more about TomoTherapy, please visit TomoTherapy.com.
©2009 TomoTherapy Incorporated. All rights reserved. TomoTherapy, Tomo,
the TomoTherapy logo and Hi·Art are among trademarks, service marks or
registered trademarks of TomoTherapy Incorporated in the United States and